AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27440084 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A9 variant rs3014866 T carriers
Number of subjects: 2684
Study 27440084 — intervention group
Group type: EXPERIMENTAL
Intervention: High SFA:carbohydrate intake in CC carriers
Number of subjects: 2684
Study 27440084 — intervention group
Group type: COMPARATOR
Intervention: Low SFA:carbohydrate intake in CC carriers
Number of subjects: 2684
Study 24446062 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg
Number of subjects: 389
Study 24446062 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg
Number of subjects: 389
Study 24446062 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 389
Study 24446062 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (all doses)
Number of subjects: 389
Study 24446062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 20561282 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise (HE)
Number of subjects: 90
Study 20561282 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (ME)
Number of subjects: 90
Study 20561282 — intervention group
Group type: COMPARATOR
Intervention: No exercise/rest (NE)
Number of subjects: 90
Study 20561282 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after exercise
Number of subjects: 90
Study 27365744 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique using face-bow
Number of subjects: 20
Study 27365744 — intervention group
Group type: COMPARATOR
Intervention: Technique avoiding face-bow
Number of subjects: 20
Study 18498914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil powder suspension (100 mg)
Number of subjects: 24
Study 18498914 — intervention group
Group type: COMPARATOR
Intervention: Cefteram pivoxil tablet (100 mg)
Number of subjects: 24
Study 15619278 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 189
Study 15619278 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 189
Study 12645861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand (20 microg/kg per day) administered subcutaneously daily for 14 days on a 28‐day cycle, monthly for four months
Number of subjects: 20
Study 12645861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle
Number of subjects: 20
Study 12645861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle
Number of subjects: 20
Study 12645861 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 peptide admixed with granulocyte‐macrophage colony‐stimulating factor and administered intradermally once every 28 days
Number of subjects: 20
Study 12645861 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 10573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazocillin (4 g piperacillin and 0.5 g tazobactam)
Number of subjects: 10
Study 8909760 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocol
Number of subjects: 0
Study 8909760 — intervention group
Group type: COMPARATOR
Intervention: Jelonet
Number of subjects: 0
Study 1873241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU
Number of subjects: 74
Study 1873241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone 500 micrograms
Number of subjects: 74
Study 1873241 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 74
Study 7050369 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (supervised exercise course, twice weekly for three months)
Number of subjects: 303
Study 7050369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303
Study 7050369 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 303
Study 7050369 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (for those with inferior MI)
Number of subjects: 303
Study 7050369 — intervention group
Group type: COMPARATOR
Intervention: Control group (for those with inferior MI)
Number of subjects: 303
Study 31641007 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR Molecular Score (OMm)
Number of subjects: 646
Study 31641007 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR Risk Score (OMclin2)
Number of subjects: 646
Study 31641007 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR Clinical Score (OMclin1)
Number of subjects: 646
Study 31641007 — intervention group
Group type: COMPARATOR
Intervention: Oncotype DX Recurrence Score (RS)
Number of subjects: 646
Study 30826759 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support programme (5 messages per week for 26 weeks)
Number of subjects: 310
Study 30826759 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 310
Study 27104841 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency stimulation (LFS)
Number of subjects: 19
Study 27104841 — intervention group
Group type: COMPARATOR
Intervention: High-frequency stimulation (HFS)
Number of subjects: 19
Study 26718299 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 60
Study 26718299 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Achyranthes aspera mouthwash
Number of subjects: 60
Study 26718299 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% Punica granatum mouthwash
Number of subjects: 60
Study 22932777 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated DHA fish oil (n=18)
Number of subjects: 36
Study 22932777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 36
Study 21617138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day n-3 PUFA
Number of subjects: 54
Study 21617138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19331721 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) once daily for 12 weeks
Number of subjects: 31
Study 19331721 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 31
Study 16476878 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE), 0.625 mg/d
Number of subjects: 10739
Study 16476878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 14761878 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-CHO (10 g/kg body mass CHO)
Number of subjects: 7
Study 14761878 — intervention group
Group type: COMPARATOR
Intervention: LOW-CHO (0.7 g/kg body mass CHO)
Number of subjects: 7
Study 11738460 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem‐Solving Treatment
Number of subjects: 430
Study 11738460 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 430
Study 11738460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 11738460 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 430
Study 9389286 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol spray (110 microg in each nostril once daily)
Number of subjects: 233
Study 9389286 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate aqueous solution spray (100 microg in each nostril once daily)
Number of subjects: 233
Study 7930715 — intervention group
Group type: COMPARATOR
Intervention: Low-risk HPV probes
Number of subjects: 62
Study 7930715 — intervention group
Group type: COMPARATOR
Intervention: Low- and high-risk HPV probes
Number of subjects: 62
Study 3129588 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen catheter
Number of subjects: 0
Study 3129588 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen catheter (bilateral)
Number of subjects: 0
Study 31144609 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity lower extremity exercise
Number of subjects: 13
Study 31144609 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 13
Study 28334510 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cream (12.5 mg)
Number of subjects: 0
Study 28334510 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cream (25 mg)
Number of subjects: 0
Study 28334510 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cream (50 mg)
Number of subjects: 0
Study 28334510 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cream (all doses)
Number of subjects: 0
Study 25726918 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 50
Study 25726918 — intervention group
Group type: COMPARATOR
Intervention: Closed method of treatment
Number of subjects: 50
Study 23224764 — intervention group
Group type: EXPERIMENTAL
Intervention: BLM-240 with 50-70% N2O in O2
Number of subjects: 216
Study 23224764 — intervention group
Group type: EXPERIMENTAL
Intervention: BLM-240 with 30% O2 in air
Number of subjects: 216
Study 23224764 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with 50-70% N2O in O2
Number of subjects: 216
Study 23224764 — intervention group
Group type: EXPERIMENTAL
Intervention: BLM-240 (both groups)
Number of subjects: 216
Study 21144724 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 50 μg once daily
Number of subjects: 33
Study 21144724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18180343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (three-dose regimen)
Number of subjects: 98
Study 18180343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (four-dose regimen)
Number of subjects: 98
Study 18180343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 98
Study 16439495 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activity recording for 6 weeks
Number of subjects: 58
Study 16439495 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 12562827 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ethanol intake study
Number of subjects: 0
Study 10712354 — intervention group
Group type: COMPARATOR
Intervention: 400 microg of budesonide plus placebo, twice daily (BUD800)
Number of subjects: 60
Study 10712354 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of budesonide plus 12 microg of formoterol, twice daily (BUD200+F)
Number of subjects: 60
Study 10712354 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD200+F and BUD800
Number of subjects: 60
Study 9088812 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70
Study 9088812 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 70
Study 8454839 — intervention group
Group type: EXPERIMENTAL
Intervention: Readables progressive‐addition lenses
Number of subjects: 36
Study 8454839 — intervention group
Group type: COMPARATOR
Intervention: Conventional spherical spectacle lenses
Number of subjects: 36
Study 3739595 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (dosage ratio 2:1)
Number of subjects: 30
Study 3739595 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 30
Study 3739595 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 30
Study 30482633 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 therapy
Number of subjects: 75
Study 27168434 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pattern of lung-function growth
Number of subjects: 684
Study 27168434 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced growth and early decline
Number of subjects: 684
Study 27168434 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced growth only
Number of subjects: 684
Study 27168434 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal growth and early decline
Number of subjects: 684
Study 27168434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-function impairment consistent with COPD
Number of subjects: 684
Study 23864515 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dancing (group A, n=18)
Number of subjects: 51
Study 23864515 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise training (group B, n=16)
Number of subjects: 51
Study 23864515 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (group C, n=17)
Number of subjects: 51
Study 21870192 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice-based conjoint analysis
Number of subjects: 104
Study 21870192 — intervention group
Group type: COMPARATOR
Intervention: Rating and ranking task
Number of subjects: 104
Study 20022572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase (0.2mg/kg/day, once daily)
Number of subjects: 32
Study 20022572 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (10mg/kg/day every 8h)
Number of subjects: 32
Study 20022572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 32
Study 20022572 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 32
Study 18508321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 7.5 microg/kg/day
Number of subjects: 40
Study 18508321 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 10 microg/kg/day
Number of subjects: 40
Study 15809475 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-DAG accumulation in post-MI patients
Number of subjects: 17
Study 15809475 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 11C-DAG accumulation with LV end-diastolic volume index
Number of subjects: 17
Study 15809475 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 11C-DAG accumulation with plasma concentration of brain natriuretic peptide
Number of subjects: 17
Study 15809475 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 11C-DAG accumulation with LV ejection fraction
Number of subjects: 17
Study 14652472 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-café group
Number of subjects: 90
Study 14652472 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 90
Study 14652472 — intervention group
Group type: COMPARATOR
Intervention: Training group
Number of subjects: 90
Study 10086255 — intervention group
Group type: EXPERIMENTAL
Intervention: Family practice return visits
Number of subjects: 509
Study 10086255 — intervention group
Group type: COMPARATOR
Intervention: Internal medicine return visits
Number of subjects: 509
Study 9101941 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium and Nd:YAG laser
Number of subjects: 0
Study 9101941 — intervention group
Group type: COMPARATOR
Intervention: Hook electrode (control)
Number of subjects: 0
Study 8517437 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Number of subjects: 20
Study 8517437 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 20
Study 8517437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3125788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg oral dose
Number of subjects: 0
Study 3125788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral dose
Number of subjects: 0
Study 3125788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg oral dose
Number of subjects: 0
Study 3125788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 100 mg intravenous infusion
Number of subjects: 0
Study 3125788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral dose with 1,000 mg probenecid
Number of subjects: 0
Study 3125788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin multiple dosing of 800 or 1,200 mg once a day over 10 days
Number of subjects: 0
Study 28992314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 60
Study 28992314 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD)
Number of subjects: 60
Study 28992314 — intervention group
Group type: COMPARATOR
Intervention: Free diet (FD)
Number of subjects: 60
Study 27630014 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (1,200 mg eicosapentaenoic acid and 600 mg docosahexaenoic acid daily)
Number of subjects: 112
Study 27630014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 27630014 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 112
Study 26228967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1%
Number of subjects: 132
Study 26228967 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops (Control)
Number of subjects: 132
Study 23706353 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition coaching (8 sessions over 6 months)
Number of subjects: 50
Study 23706353 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline only)
Number of subjects: 50
Study 20526388 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel bisulfate (Plavitor)
Number of subjects: 20
Study 20526388 — intervention group
Group type: COMPARATOR
Intervention: Original clopidogrel bisulfate (Plavix)
Number of subjects: 20
Study 18506608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 98
Study 18506608 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without AF)
Number of subjects: 98
Study 16804391 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive biological predictive score (C-reactive protein >20 mg/L and erythrocyte sedimentation rate >15 mm)
Number of subjects: 71
Study 16804391 — intervention group
Group type: COMPARATOR
Intervention: Negative biological predictive score (both markers lower than limits)
Number of subjects: 71
Study 12792351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) replacing d4T (group 1)
Number of subjects: 30
Study 12792351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) replacing PI or NNRTI (group 2)
Number of subjects: 30
Study 12792351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) plus AZT replacing d4T and PI or NNRTI (group 3)
Number of subjects: 30
Study 12792351 — intervention group
Group type: COMPARATOR
Intervention: Control group (d4T with PI or NNRTI)
Number of subjects: 30
Study 10334517 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU infusion and bolus CF with standard whole pelvic RT
Number of subjects: 368
Study 10334517 — intervention group
Group type: COMPARATOR
Intervention: Oral HU with standard whole pelvic RT
Number of subjects: 368
Study 7710725 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (group 1a)
Number of subjects: 146
Study 7710725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonregular exercise (group 1b)
Number of subjects: 146
Study 7710725 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 146
Study 2667385 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-silicone graft
Number of subjects: 30
Study 2667385 — intervention group
Group type: COMPARATOR
Intervention: Conventional PTFE grafts
Number of subjects: 30
Study 414287 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 414287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31914880 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted Atrial Fibrillation (AF)
Number of subjects: 1030836
Study 31914880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization-Egger
Number of subjects: 1030836
Study 31219252 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 52
Study 31219252 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Training (TT)
Number of subjects: 52
Study 31219252 — intervention group
Group type: COMPARATOR
Intervention: Stretching Group (SG)
Number of subjects: 52
Study 28493642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 152
Study 28493642 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 152
Study 25088308 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy triage assessment
Number of subjects: 208
Study 25088308 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 208
Study 23983725 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding during vaccination
Number of subjects: 144
Study 23983725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray before vaccination
Number of subjects: 144
Study 23983725 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study 21565328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) with interoceptive exposure (IE) to visceral sensations
Number of subjects: 110
Study 21565328 — intervention group
Group type: COMPARATOR
Intervention: Stress management (SM)
Number of subjects: 110
Study 21565328 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 110
Study 20009494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 118
Study 20009494 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 118
Study 20009494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 118
Study 16229053 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate information about cervical cancer screening
Number of subjects: 0
Study 16229053 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective information on an improvement to the screening programme
Number of subjects: 0
Study 16229053 — intervention group
Group type: COMPARATOR
Intervention: No information provided
Number of subjects: 0
Study 15554982 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered by anesthetists
Number of subjects: 0
Study 15554982 — intervention group
Group type: COMPARATOR
Intervention: Propofol administered by registered nurses
Number of subjects: 0
Study 11529850 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (PSCT)
Number of subjects: 204
Study 11529850 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 204